OTCMKTS:BIXT Bioxytran Q1 2025 Earnings Report $0.03 0.00 (0.00%) As of 06/18/2026 03:31 PM Eastern ProfileEarnings History Bioxytran EPS ResultsActual EPS-$0.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABioxytran Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABioxytran Announcement DetailsQuarterQ1 2025Date5/15/2025TimeAfter Market ClosesConference Call DateWednesday, May 14, 2025Conference Call Time6:00PM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Bioxytran Earnings HeadlinesBioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25May 29, 2026 | globenewswire.comBioxytran Delays Annual 10-K FilingApril 1, 2026 | tipranks.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free. | Behind the Markets (Ad)Bioxytran Raises Capital to Advance Development and CommercializationMarch 20, 2026 | tipranks.comBIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENTMarch 20, 2026 | globenewswire.comBioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-MMarch 4, 2026 | globenewswire.comSee More Bioxytran Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bioxytran? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioxytran and other key companies, straight to your email. Email Address About BioxytranBioxytran (OTCMKTS:BIXT) is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings. Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release. These formulations are engineered to minimize oxidative stress and inflammation while enhancing tissue recovery. The company maintains a patent portfolio covering key geographies, including North America, Europe, and Asia, and is actively exploring collaborative partnerships to support development and potential global commercialization. Originating from foundational work in synthetic oxygen therapeutics, Bioxytran has transitioned from early-stage research into a specialized biopharmaceutical developer. The management team brings together expertise in biotechnology R&D, regulatory strategy, and manufacturing scale-up. Bioxytran continues to pursue strategic alliances and funding initiatives to advance its mission of delivering innovative oxygen-based therapies that improve patient outcomes in critical therapeutic areas.View Bioxytran ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Satellogic Is Tiny But Its Revenue Growth Is Hard to IgnoreAehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?Why Kroger’s Pullback Could Be a Gift for Patient InvestorsCredo Technologies Accelerates AI—Its Stock Price Will FollowWhy Palantir’s Google Cloud Deal Could Change the DebateAmerican Eagle’s Q1 Beat Leaves Investors With a Bigger QuestionCarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
